Abstract:Objectives Multiple warfarin pharmacogenetic algorithms have been published and been confirmed to predict warfarin dose more accurately than clinical algorithm or fixed-dose approach. However, their performance in Chinese patients has never been evaluated. We sought to compare the performance of published warfarin pharmacogenetic algorithms in a cohort of Chinese patients under warfarin anticoagulation. Methods The study population consisted of 282 unrelated Han-Chinese patients consecutively admitted to the General Hospital of Chinese People9s Liberation Army between January 2008 and July 2011. The patients had all undergone warfarin anticoagulation for various indications and were stably controlled with a target international normalisation ratio (INR) of 1.6–2.5. Genomic DNA extraction from each patient was followed by genotyping to detect the polymorphisms of CYP2C9*3 (rs1057910), VKORC1 −1639 G/A (rs9923231), and CYP4F2*3 (rs2108622) respectively, using standard techniques. A total of 8 eligible pharmacogenetic algorithms were selected for performance comparison. The performance of each algorithm was evaluated by calculating the percentage of patients whose predicted dose fell within 20% of their actual therapeutic dose (percentage within 20%), and the mean absolute error (MAE) between each predicted dose and actual stable dose. Results In the entire cohort, the pharmacogenetic algorithms could predict warfarin dose with the average MAE of 0.87±0.17 mg/day (0.73–1.17 mg/day), and the average percentage within 20% of 43.8%±8.1% (29.1–52.1%). By pair wise comparison, warfarin dose prediction was significantly more accurate with the algorithms derived from Asian patients (48.6–50.0%) than those from Caucasian patients (29.1–39.7%; OR 1.61–3.36, p≤0.02). Algorithms with additional covariates of INR values or CYP4F2*3 performed better than those without the covariates (adding INR: OR: 1.71 (1.08–2.72), p=0.029; adding CYP4F2*3: OR: 2.67 (1.41–5.05), p=0.004). When the patients were stratified according to the dose range, the algorithms from Caucasian and racially mixed populations tended to perform better in higher dose group (≥4.5 mg/day), and algorithms from Asian populations performed better in intermediate dose group (1.5–4.5 mg/day). None of the algorithms performed well in lower dose group (≤1.5 mg/day). Conclusions Our study indicated that none of the eligible pharmacogenetic algorithms could perform the best for all dosing ranges in the present cohort of Chinese patients under warfarin anticoagulation. It may be important to consider the ethnic and clinical specific characteristics when choosing the appropriate algorithm for a local service population. A more refinement pharmacogenetic algorithm combining 3 genotypes (CYP2C9, VKORC1 and CYP4F2) and clinical factors with INR response could potentially improve the warfarin dose prediction in Chinese patients.

Comparison of the Performance of the Warfarin Pharmacogenetics Algorithms in Patients with Surgery of Heart Valve Replacement and Heart Valvuloplasty.

Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients.

Comparative Performance of Gene-Based Warfarin Dosing Algorithms in Chinese Patients

Comparative performance of pharmacogenetics-based warfarin dosing algorithms in Chinese population: use of a pharmacokinetic/pharmacodynamic model to explore dosing regimen through clinical trial simulation

Randomized Study of Efficiency and Safety of Antithrombotic Therapy with Warfarin in Nonvalvular Atrial Fibrillation

Accuracy Assessment of Pharmacogenetic Algorithms for Warfarin Dose Prediction in Chinese Patients

[Clinical Study of Anticoagulation with Warfarin and Heparin in Patients after Mechanical Valve Replacement].

Association between gene polymorphisms and initial warfarin therapy in patients after heart valve surgery

Development of A Novel Individualized Warfarin Dose Algorithm Based on A Population Pharmacokinetic Model with Improved Prediction Accuracy for Chinese Patients after Heart Valve Replacement

A clinical study of genetic testing to guide the dosing of warfarin after heart valve replacement

Establishment of a Han Chinese-specific pharmacogenetic-guided warfarin dosing algorithm.

Combining Portable Coagulometers with the Internet: A New Model of Warfarin Anticoagulation in Patients Following Mechanical Heart Valve Replacement

Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials.

Research on single nucleotide polymorphism with initial anticoagulative effect and maintenance dose of ;Warfarin

New Internet-Based Warfarin Anticoagulation Management Approach After Mechanical Heart Valve Replacement: Prospective, Multicenter, Randomized Controlled Trial

Estimation of the Warfarin Dose with A Pharmacogenetic Refinement Algorithm in Chinese Patients Mainly under Low-Intensity Warfarin Anticoagulation

Optimizing the Dynamic Treatment Regime of In-Hospital Warfarin Anticoagulation in Patients after Surgical Valve Replacement Using Reinforcement Learning

Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients

Estimate the Warfarin Dose by Ensemble of Machine Learning Algorithms

Construction and Validation of A Pharmacogenetic Refinement Algorithm for the Estimation of the Warfarin Dose in Chinese Patients

Anticoagulation of Warfarin Therapy in Patients after Mechanical Valve Implantation